Masimo Co. (NASDAQ:MASI) Receives $179.67 Consensus Target Price from Analysts

Masimo Co. (NASDAQ:MASI) has been given an average rating of “Moderate Buy” by the seven research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $179.67.

Several equities analysts have commented on MASI shares. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company upped their price target on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Finally, BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. grew its position in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the period. GAMMA Investing LLC grew its holdings in shares of Masimo by 136.5% during the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after buying an additional 269 shares during the last quarter. HHM Wealth Advisors LLC increased its position in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Masimo during the 2nd quarter valued at approximately $109,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Performance

NASDAQ:MASI opened at $171.23 on Wednesday. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a 50 day moving average price of $165.55 and a 200 day moving average price of $137.46. The stock has a market capitalization of $9.17 billion, a P/E ratio of 118.09 and a beta of 1.01.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period last year, the business posted $0.63 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Equities research analysts forecast that Masimo will post 4.03 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.